Abstract PD3-09: Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network
Prospective analysis characterizes mechanisms of resistance to antibody drug conjugates in metastatic breast cancer, indicating new treatment strategies.
Key Points
To understand mechanisms driving resistance to antibody drug conjugates in metastatic breast cancer.
Characterized paired primary and metastatic samples via multiplatform profiling.
Analyzed tumor samples using DNA sequencing, methylation arrays, and RNA sequencing.
Performed gene expression comparisons and pathway analysis using statistical methods.
168 patients analyzed with data from various platforms.
Significant decrease in ERBB2 expression in some HER2+ patients after treatment with HER2 ADC.
Pathway analysis revealed differences in pathways related to treatment, including DNA damage repair and lysosomal processing.
Cite This Study
Garrido-Castro et al. (2026) studied this question.